This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           Jan. 29, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Addition of tirapazamine to cisplatin chemoradiotherapy did not improve PFS in cervical cancer
Healio
The addition of the hypoxic cell sensitizer tirapazamine to a cisplatin chemoradiotherapy regimen did not improve PFS in patients with cervix cancer compared with cisplatin chemoradiotherapy alone, according to study results. The prospective, randomized phase 3 trial — conducted by the Gynecologic Oncology Group and National Cancer Institute of Canada Clinical Trials Group — evaluated 402 patients with stage IB2 or IIA (tumor size >4 cm) or IIB, IIIB or IVA cervical carcinoma restricted to the pelvis.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




OVARIAN CANCER


GOG completes patient enrollment in GOG-0212 Phase 3 clinical trial of paclitaxel poliglumex (opaxio(TM)) as maintenance therapy in ovarian cancer
Cell Therapeutics Press Release
Cell Therapeutics, Inc. (CTI) announced that the Gynecologic Oncology Group (GOG) informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer. "Although initial treatment is effective in putting this disease in remission, there is a high relapse rate for patients with ovarian cancer and there are limited treatment options when their cancer returns," said Larry J. Copeland, M.D., Department of Obstetrics and Gynecology, Ohio State University Comprehensive Cancer Center, Group Vice Chair of the GOG and chair of the GOG-0212 study.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Surgery, surveillance may obviate chemotherapy in 50 percent of stage I pediatric malignant ovarian germ cell tumors
Healio
A strategy of surgical resection followed by surveillance can eliminate the need for 50 percent of patients with stage I pediatric malignant ovarian germ cell tumor to undergo chemotherapy, according to findings from the Children’s Oncology Group. Researchers evaluated 25 girls aged 0 to 16 years with stage I malignant ovarian germ cell tumor (MOGCT) between November 2003 and July 2011.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  Work for the best

We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201.
 


GENETICS


Inherited gene mutations found in 20 percent of women with ovarian cancer
Medical News Today
According to a study published in Nature Communications, genetic studies of inherited predisposition to ovarian cancer have tended to focus on women with a known family history of the disease. Now, a new study of ovarian cancer patients with no known family history of the disease found one fifth of them had inherited alterations in genes known to be linked to ovarian and breast cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Study provides clearer picture of cancer risk
Medical Xpress
A University of Vermont researcher has helped to develop a more accurate way of studying genetic changes to identify people at high risk for colon and other cancers. The findings are published in Nature Genetics. Marc Greenblatt, M.D. and Fletcher Allen Health Care co-led a collaborative global effort to interpret genetic data related to hereditary colon cancer. The team's findings will both allow doctors to access publicly-available data to more effectively interpret risks and give patients a more accurate picture of familial risk for colon, Lynch syndrome and other cancers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


UTERINE CANCER


Uterine cancer surgery: The clock is ticking
Medscape (Free login required)
Dr. Maurie Markman discusses an article that appeared in the Journal of Clinical Oncology. The article asks the question of whether it matters how long a particular type of patient — in this case, women with endometrial cancer — must wait to have definitive surgery in a healthcare system that is constrained with an adequate number of surgeons, and says that patients have to wait a month, or 2 months or 3 months, for surgery because we just don't have the facilities available.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Advertisement
A Medical
‘Must Have’

Morrow’s Gynecologic Cancer Surgery, 2nd Edition is an invaluable comprehensive surgical text book resource containing step-by-step written and illustrated descriptions of all the important operations in the field of gynecologic oncology.
Advertisement
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


HPV


Large-scale HPV self-testing proves effective for screening cervical cancer
Science Daily
Self-testing for human papillomavirus (HPV) is as effective at detecting cancer as a conventional smear test (cytology screening) even when scaled up to test large populations. Researchers from Queen Mary University of London conducted a pilot study of 100,242 Mexican women — the largest study of its kind — aged 25-75 and from low-income backgrounds. Around 11 percent of women tested positive for HPV (10,863 women).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




HPV test awareness, knowledge still low
Reuters
Americans are more aware that there is a test for the human papillomavirus (HPV) than counterparts in the U.K. and Australia, according to a new study, but few people knew much more than that. "Awareness of HPV has tended to be low but has been rising since the introduction of testing and vaccination," said Jo Waller, the study's senior author.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


Breast cancer: Don't delay chemotherapy
Medpage Today
Delaying adjuvant chemotherapy for breast cancer more than 60 days significantly increased the odds of premature death and distant metastasis, a review of almost 7,000 cases showed. As compared with starting adjuvant therapy within 30 days of surgery, initiating chemotherapy at 61 days or later was associated with a 19 percent increase in the risk of premature death.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Jan. 22, 2014
Jan. 15, 2014
Jan. 8, 2014
Jan. 3, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063